fexofenadine hydrochloride and pseudoephedrine hydrochloride
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION (fexofenadine hydrochloride and pseudoephedrine hydrochloride) by Sanofi. Approved for these symptoms due to hay fever, other upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchy, watery eyes ▪ itching of the nose and 4 more indications. First approved in 2004.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
Allegra-D 24 Hour is a fixed-dose combination oral tablet combining fexofenadine hydrochloride (a non-sedating antihistamine) and pseudoephedrine hydrochloride (a decongestant) in extended-release formulation. It treats symptoms of hay fever and upper respiratory allergies including runny nose, sneezing, itchy/watery eyes, nasal congestion, and sinus pressure. The fexofenadine blocks histamine receptors to reduce allergic symptoms while pseudoephedrine constricts nasal blood vessels to relieve congestion.
As lifecycle approaches loss of exclusivity, brand teams face margin pressure and shrinking resources; roles increasingly focus on managed care, generic transition planning, and portfolio rebalancing.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Allegra-D 24 Hour offers limited growth opportunity but valuable experience in late-lifecycle brand management, generic transition strategy, and OTC commercialization. Roles available are primarily in managed care access, field sales defense, and compliance rather than innovation or launch-phase expansion.